Fatigue is highly prevalent among multiple sclerosis (MS) patients and has pervasive adverse effects on daily functioning and quality of life. The investigators found in a recent study that obstructive sleep apnea-hypopnea (OSAH) is the most common sleep abnormality in multiple sclerosis (MS) patients. There was also a significant relationship between OSAH and higher fatigue scores in MS patients. Preliminary work from the investigators in this group of subjects shows that treatment of sleep disorders (mostly OSAH) can improve fatigue and other symptoms in some MS patients. However, it is now necessary to systemically test the effect of OSAH treatment in a randomized, controlled study, to be sure that it really does improve fatigue and other symptoms. The best treatment for OSAH in the general population is continuous positive airway pressure (CPAP). This treatment has been well tolerated by most MS patients who have used the device at the investigators' center. This project will therefore be a randomized, controlled, clinical trial of CPAP in MS patients with OSAH. The effects of six months of CPAP treatment on fatigue as well as sleep quality, somnolence, pain, disability, and quality of life will be studied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
49
McGill University Health Centre
Montreal, Quebec, Canada
Fatigue Severity Scale
Time frame: Six months
Fatigue Scale for Motor and Cognitive Functions
Time frame: Three & Six months
Epworth Sleepiness Scale
Time frame: Three & Six months
Pittsburgh Sleep Quality Index
Time frame: Three & Six months
Pain visual analog scale
Time frame: Three & Six months
Multiple Sclerosis-specific quality of life measure-54 (MSQOL-54)
Time frame: Three & Six months
Fatigue Severity Scale
Primary outcome measure is FSS at six months
Time frame: Three months
Expanded Disability Status Scale
Standard scale for evaluation of Multiple Sclerosis-related disease disability
Time frame: Three & Six months
Center for Epidemiological Studies-Depression Scale
Time frame: Three & Six months
Cognitive evaluation
Montreal Cognitive Assessment (MoCA) and Tower of London-Drexel University
Time frame: Six months
Polysomnographic variables
Standard complete polysomnographic measures of sleep and respiration
Time frame: Six months
Objective CPAP compliance
Standard measures of CPAP use and efficacy from machine microprocessor
Time frame: Three and Six Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.